1. Introduction {#s0005}
===============

Kinases represent ideal targets for rational combination therapies due to their well-established druggability ([@bb0055], [@bb0255]). Many tumors, however, still express undruggable oncoproteins and therefore the design of rational combination therapies that target several of their effector pathways or create a synthetic lethal condition in oncoprotein expressing cells has become a major topic in oncology ([@bb0150]).

Indeed, mutations in the three hitherto undruggable RAS proteins (K-Ras, N-Ras, H-Ras) represent major drivers in cancer, leading to chronic activation of the PI3K-AKT and RAF-MEK-ERK pathways ([@bb0040], [@bb0085], [@bb0135], [@bb0315]). Therefore, the field has focused on efficient targeting of the kinases in the RAS effector pathways, in particular the MEK-ERK kinases and the PI3K-PDK axis ([@bb0085], [@bb0135]). Other effectors such as the JAK-STAT and NF-κB signaling pathways are also chronically activated in *RAS* mutant cells ([@bb0305], [@bb0420]). Rational drug combinations that exploit cancer specific vulnerabilities while avoiding toxic side-effects, however, will require an in-depth knowledge about the complexities of these pathways, in particular their intricate regulation by protein complex formation, feedback- and robustness phenomena ([@bb0120], [@bb0340]). A major step in this direction is therefore the identification of novel druggable proteins such as kinases that could be further developed as additional targetable nodes in oncoprotein networks, for example by creating synthetic lethal constellations ([@bb0070]). Surprisingly, the majority of to date investigated kinases represents \< 10% of the kinome and has already been known prior to the human genome project ([@bb0075]). Thus, there is a long tail of under-researched and ill-defined kinases that might represent promising drug targets, either on their own or in combinatorial settings.

Previously, we have reported an RNA interference screen for kinases modulating aberrant signaling by the G13E mutant of the *LET-60* RAS orthologue in *Caenorhabditis elegans* ([@bb0405]). This mutation affects the evolutionary conserved glycine residue that is frequently mutated in the RAS proteins in human tumors ([@bb0040]). In this screen, knockdown of RIOK1, a member of the RIO protein kinase family, led to a strong suppression of the well-characterized RAS^G13E^ driven multi-vulva phenotype.

RIO kinases represent a family of ancient atypical protein kinases found in all kingdoms of life. Compared to typical eukaryotic protein kinases, they lack substrate recognition sites and conserved activation loop motifs, although they hydrolyze ATP *in vitro* ([@bb0010], [@bb0210], [@bb0215], [@bb0220]). The *Saccharomyces cerevisiae* orthologues, Rio1 and Rio2, were originally identified and characterized as essential genes for cell cycle progression and ribosomal biogenesis ([@bb0010], [@bb0220], [@bb0400]). Their abundance and kinase activity are critical for maturation of the 40S small ribosomal subunit ([@bb0095], [@bb0100]). RIO proteins deficient for ATP-binding or for catalytic activity impair ribosomal biogenesis and delay cell cycle exit ([@bb0025], [@bb0095], [@bb0215], [@bb0410]). Several studies also confirmed these functions in mammalian cells for RIOK1, RIOK2 and, for the metazoan specific third member of the family, RIOK3 ([@bb0025], [@bb0410], [@bb0430]). However, only a few substrates for RIO kinases have been identified so far ([@bb0155], [@bb0380]) and besides their involvement in ribosomal biogenesis, additional and potentially isoform-specific functions remain to be characterized.

Importantly, RIO kinases are overexpressed in various cancer types, although the functional significance remains unknown. RIOK1 overexpression has been observed in colorectal cancer ([@bb0240]) and in non-small cell lung cancer (NSCLC). In the latter, RIOK1 was co-overexpressed with the growth promoting proteins MAPJD (Myc-associated protein with JmjC domain) and PRMT5 (protein arginine methyl transferase 5) ([@bb0125], [@bb0375]). RIOK2 is overexpressed in glioblastoma ([@bb0325]) and NSCLC ([@bb0245]). RIOK3 has been associated with remodeling of the cytoskeleton in hypoxia-driven metastases of breast cancer cells ([@bb0360]). Together with our identification of RIOK1 as an enhancer of oncogenic RAS signaling in *C. elegans* ([@bb0405]), the aberrant expression of human RIO kinases in cancer, in particular in carcinoma entities with high frequencies of *RAS* mutations, suggests a conserved role of RIO kinases in the RAS signaling network. Therefore, we characterized the role of these ill-defined atypical kinases in various mammalian tumor cell lines by functional and proteomic approaches. We show that loss of RIOK1 expression specifically impairs the phenotype of RAS-transformed colon-, lung- and breast cancer cells.

2. Material and Methods {#s0010}
=======================

2.1. Tissue Culture and Generation of Inducible Knockdown Cell Lines {#s0015}
--------------------------------------------------------------------

The following cell lines were used in this study: NCI-H1299, MDA-MB-231, HEK293T, Plat-E, Caco-2, RKO, SW480, HCT116, K562 and MCF-10A. NCI-H1299, MDA-MB-231, SW480, RKO, HCT116, Caco-2, HEK293T and Plat-E cell lines were cultivated in DMEM with 10% FCS. K562 cells were cultivated in RPMI with 10% FCS. MCF-10A cells were cultivated as described previously ([@bb0145]). NCI-H1299 cells were provided by the BIOSS toolbox, the central repository of the Centre for Biological Signalling Studies, University of Freiburg. RKO cells were a kind gift of Prof. Nils Blüthgen, Berlin ([@bb0120]). The source of all other cell lines has been described elsewhere ([@bb0120], [@bb0140], [@bb0145], [@bb0230], [@bb0415]). Knockdown cell lines were generated by lentiviral infection using the pTRIPZ system (Dharmacon). Constructs used in this study: non-silencing: \#RHS4743; shRIOK1_1: \#RHS4696-200770120, shRIOK1_2: \#RHS4696-200769994, shRIOK1_3: \#RHS4696-200769020, shRIOK1_4: \#RHS4696-200773349; shRIOK2: \# RHS4696-201898580; shRIOK3: \# RHS4430-200288078. Cell lines were established according to the instructions of the manufacturer and selected with puromycin (AppliChem). Cells were maintained in respective medium with puromycin. For experiments, cells were induced in medium containing 0,5--1 μg/ml doxycycline (Sigma-Aldrich) without puromycin. For all experiments knockdown was induced 3--4 days in advance. Non-induced and non-silencing cells served as controls; induced non-silencing cells served as reference for quantifications.

2.2. Generation of cDNA Expression Vectors {#s0020}
------------------------------------------

The following cDNA expression vectors were used in this study: pBabe luciferase, pMIBerry RIOK1myc WT, pMIBerry RIOK1myc D324A, pMIBerry RIOK1myc D324N, pMIBerry RIOK1HA WT, pMIBerry RIOK3HA WT, pCMV e.V., pCMVFLAG-IKK (WT, KD, CA). RIOK1 cDNA with C-terminal myc-or HA-tag was amplified with Phusion polymerase (Thermo Scientific) from pDONR223 RIOK1 (Addgene) and cloned in pMIBerry ([@bb0335]) using the *Xho*I restriction site. D324 was mutated by side-directed-mutagenesis using respective primers and *Pfu* ultra plolymerase (Agilent Technologies). RIOK3 cDNA with C-terminal HA-tag was amplified from pDONR223 RIOK3 (Addgene) with Phusion polymerase and cloned in pMIBerry using *Xho*I and *BamH*I. The pCMV IKK constructs were obtained from Addgene ([@bb0285]). The empty pCMV control vector (e.V.) was generated from pCMV FLAG-IKK WT by restriction digest with *Hind*III and *Cla*I, excising FLAG-IKK, followed by a blunt ligation with T4. All constructs were verified by sequencing.

The following oligonucleotides were used in this study (in 5′ to 3′direction):RIOK1 *Xho*I fwd: TT*CTCGAG*GGCACCATGGACTACCGGCGGCTTCTCATG.RIOK1 **myc** *Xho*I rev: TT*CTCGAG*GGGTTA**CAGGTCCTCCTCTGAGATCAGCTTCTGCTC**TTTGCCTTTTTTCGTCTTGGCTGTCTTCTCCTTTCTTTTTTTCACRIOK1 **HA** *Xho*I rev: CCTC*CTCGAG*GGGTTA**AGCGTAGTCTGGGACGTCGTATGGGTA**TTTGCCTTTTTTCGTCTTGGCTGTCTTCTCCTTTCTTTTTTTCACATGTTTRIOK3 *Xho*I fwd: TTGGC*CTCGAG*GGCACCATGGATCTGGTAGGAGTGGCATCGCCRIOK3 **HA** *BamH*I rev: CCCGGG*GGATCC*GTTGGATTA**AGCGTAGTCTGGGACGTCGTATGGGTA**TTCATCATATAGTAGTGGTGGGTCTCCATCATCTTTCAAAAATGAAGCAGCRIOK1 D324A fwd: GCCAGACTTGTCCATGCAGCTCTCAGTGAATTTAACATG.RIOK1 D324A rev: CATGTTAAATTCACTGAGAGCTGCATGGACAAGTCTGGCRIOK1 D324N fwd: CAGGATGCCAGACTTGTCCATGCAAATCTCAGTGAATTTAACATGCTGRIOK1 D324N rev: CAGCATGTTAAATTCACTGAGATTTGCATGGACAAGTCTGGCATCCTG

2.3. Antibodies and Western Blot Analysis {#s0025}
-----------------------------------------

Cell lysis, SDS-PAGE and Western blot were performed as described in ([@bb0140]). Blotted proteins were visualized and quantified using a Fusion Solo (Peqlab) chemo-luminescence imager and the included software.

Antibodies (with RRID, if available) used in this study were:

14-3-3 (H8) (Santa Cruz AB_626618); 9E10 myc (generated in-house from the 9E10 hybridoma cell line ([@bb0090])), HA 3F10 (Roche Applied Science AB_390919), AKT (Cell Signaling AB_329827); phospho-AKT(S473) (Cell Signaling AB_2315049); Aurora A (Cell Signaling 12,100); Aurora B (BD AB_398396); Cyclin A2 (Cell Signaling AB_2071958), Cyclin B1 (Cell Signaling 12,231); Cyclin D1 (Cell Signaling AB_10839128), Cyclin E2 (Cell Signaling AB_2071197); CDK1 (Cell Signaling AB_2074795), phospho-CDK1 (Y15) (Cell Signaling AB_331460); FLAG (M2) (Sigma-Aldrich AB_439685), pIκBα S32 (Cell Signaling AB_561111), IκBα (Cell Signaling AB_331623); MTDH (Invitrogen AB_2533475); Lamin B (D9V6H) (Cell Signaling 13,435); P65 (Cell Signaling AB_10859369); phospho-P65 (Ser536) (Cell Signaling AB_331284); RIOK1 (abcam AB_2042809); RIOK2 (abcam AB_2042810); RIOK3 (SUDD (RS-31)) (Santa CruzAB_2178113); Stathmin1 (Cell Signaling 3352); phospho-Stathmin1 (S38) (Cell Signaling AB_10544408); Tubulin (B5-1-2) (Santa Cruz AB_628410). Secondary α-mouse HRP, α-rabbit HRP and α-goat HRP antibodies were purchased from Santa Cruz. Bay 11--7082 was purchased from SelleckChem.

Western Blots were developed with the PeqlabTM Fusion Solo and densitometrically analyzed with the Fusion software (ver. 16.08). Quantification for Western Blots is shown in [Table S4](#ec0025){ref-type="supplementary-material"}.

2.4. Co-immunoprecipitation Studies {#s0030}
-----------------------------------

For co-immunoprecipitation studies, Plat-E cells ([@bb0300]) were transfected with 8 μg expression vectors, lysed 48 h later and the immunoprecipitation against the myc-tag was carried out as described previously ([@bb0335]).

2.5. 3D Matrix Growth and Microscopy {#s0035}
------------------------------------

Five thousand cells were seeded, grown in 2% Matrigel® (BD Bioscience), cultivated and fixed as described previously ([@bb0145]). E-Cadherin staining (BD Bioscience AB_397580), F-Actin staining (Phalloidin Alexa 488 (Cell Signaling 8878)) and DAPI ProLong® Gold (LifeTechnologie P36931) were applied according to manufacturer\'s protocol.

Living fluorescent cells, cultured conventionally or in 3D matrix, were imaged with the ZEISS AxioObserver Z1 wide field microscope with a 10 × A-Plan 0.25 air objective connected to an AxioCamMRm camera. For fixed cells and immuno-fluorescent stainings, the ZEISS AxioObserver Z1 plus ApoTome2 was used. Images were taken with a 10 × A-Plan 0.25 air objective or a 40 × PlanNeoFluar 1.3 oil objective, respectively. For IHC images the ZEISS Axioskop2 with a 10 × PlanNeoFluor 0.17 air objective was used.

2.6. Mass Spectrometry Analysis of SILAC Labeled NCI-H1299 Cells {#s0040}
----------------------------------------------------------------

### 2.6.1. Cell Culture and Stable Isotope Labeling {#s0045}

Cells were subcultured and passaged in SILAC-DMEM (Thermo Fisher Scientific, Langenselbold, Germany) supplemented with 10% dialyzed FBS (Gibco, Invitrogen), 1% [l]{.smallcaps}-glutamine (PAN Biotech), 42 mg/l [l]{.smallcaps}-arginine (Sigma-Aldrich), 73 mg/l [l]{.smallcaps}-lysine (Sigma-Aldrich) and 82 mg/l proline (Sigma-Aldrich). According to the experimental setup cells were cultured and fully labeled for two weeks in the same way but through incorporation of [l]{.smallcaps}-arginine-13C6-15 N4 and [l]{.smallcaps}-lysine-13C615N2 (Arg10 Lys8; Cambridge Isotope Laboratories).

### 2.6.2. MS Sample Preparation {#s0050}

Samples were lysed in SDS-PAGE loading buffer, reduced with 1 mM DTT (Sigma-Aldrich) for 5 min at 95 °C and alkylated using 5.5 mM iodoacetamide (Sigma-Aldrich) for 30 min at 25 °C in the dark. Protein mixtures were separated by SDS-PAGE using 4--12% Bis-Tris mini gradient gels (NuPAGE, Life Technologies). The gel lanes were cut into 10 equal slices, which were in-gel digested with trypsin (Promega, Mannheim, Germany) ([@bb0350]) and the resulting peptide mixtures were processed on STAGE tips as described ([@bb0320]).

### 2.6.3. MS {#s0055}

Mass spectrometric measurements were performed on LTQ Orbitrap XL mass spectrometer (Thermo Fisher Scientific, Bremen, Germany) coupled to an Agilent 1200 nanoflow-HPLC (Agilent Technologies GmbH, Waldbronn, Germany) essentially as described in ([@bb0365]). HPLC-column tips (fused silica) with 75 μm inner diameter (New Objective, Woburn, MA, USA) were self-packed with Reprosil-Pur 120 ODS-3 (Dr. Maisch, Ammerbuch, Germany) to a length of 20 cm. Samples were applied directly onto the column without pre-column. A gradient of A \[0.5% acetic acid (high purity, LGC Promochem, Wesel, Germany) in water\] and B \[0.5% acetic acid in 80% ACN (LC-MS grade, Wako, Germany) in water\] with increasing organic proportion was used for peptide separation (loading of sample with 2% B; separation ramp: from 10% to 30% B within 80 min). The flow rate was 250 nl/min and for sample application 500 nl/min. The mass spectrometer was operated in the data-dependent mode and switched automatically between MS (max. of 1 × 106 ions) and MS/MS. Each MS scan was followed by a maximum of five MS/MS scans in the linear ion trap using normalized collision energy of 35% and a target value of 5000. Parent ions with a charge state from z = 1 and unassigned charge states were excluded for fragmentation. The mass range for MS was *m*/*z* = 370 to 2000. The resolution was set to 60,000. Mass-spectrometric parameters were as follows: spray voltage 2.3 kV; no sheath and auxiliary gas flow; ion-transfer tube temperature 125 °C.

### 2.6.4. Identification of Proteins and Protein Ratio Assignment Using MaxQuant {#s0060}

The MS raw data files were uploaded into the MaxQuant software version 1.3.05 ([@bb0045]), which performs peak detection, SILAC-pair detection, generates peak lists of mass error corrected peptides and data base searches. A full length uniprot database (based on uniprot human version July 2012) was employed together with reverse annotations of all sequences. Carbamidomethylcysteine was set as fixed modification, methionine oxidation and protein amino-terminal acetylation were set as variable modifications. Double SILAC was chosen as quantitation mode. Three miss cleavages were allowed, enzyme specificity was trypsin/P + DP, and the MS/MS tolerance was set to 0.5 Da. The average mass precision of identified peptides was in general \< 1 ppm after recalibration. Peptide lists were further used by MaxQuant to identify and relatively quantify proteins using the following parameters: peptide, and protein false discovery rates (FDR) were set to 0.01, maximum peptide posterior error probability (PEP) was set to 0.1, minimum peptide length was set to 7, minimum number of peptides for identification and quantitation of proteins was set to two of which one must be unique, and identified proteins have been re-quantified. The "match-between-run" option (2 min) was used.

### 2.6.5. Data Analysis {#s0065}

Data were loaded into the freely available Perseus software and log2 transformed ([@bb0050]). Significance B (permutation based FDR ≤ 0.05) was used to identify significantly up-and down regulated proteins between control and knockdown cells. To address the biological implications of identified proteins they were analyzed by STRING ([@bb0115]) for interactions (default parameters) and resulting networks were visualized by cytoscape (<http://www.cytoscape.org>/).

2.7. Colony Formation Assay {#s0070}
---------------------------

Five hundred cells were seeded in 6 well plates and grown for up to 13 days. Cell colonies were fixed and stained with Giemsa (Carl-Roth). Plates were imaged and cell density per well was determined by pixel density measurement using Photoshop CS2.

2.8. Luciferase Reporter Assay {#s0075}
------------------------------

Cells were seeded in low density (2--4 × 10^4^) in 24 well plates, allowed to attach and transfected with 10 ng pRL CMV Renilla (kindly provided by Andreas Hecht, IMMZ Freiburg) and 500 ng 2xHIVκBLuc Firefly ([@bb0295]). In the case of IKK2 co-transfection, 1 μg pCMV empty vector or FLAG-IKK (WT/KD/CA) was used. After 48 h cells were lysed in luciferase lysis buffer and luciferase activity was determined as described in ([@bb0330]).

2.9. MTT Cell Viability Test {#s0080}
----------------------------

One to three thousand cells were seeded in 96-Well plates and grown for up to four days. For MTT measurement, medium was exchanged to MTT solution (medium with 0.45 mg/ml Thiazolyl Blue Tetrazolium Bromide (Sigma-Aldrich)). After incubation at 37 °C for 2 h, medium was aspirated and formed crystals were dissolved in 150 μl DMSO. Absorption at 590 nm was measured with a plate reader (Tecan plate reader). MTT activity was determined each day beginning with day 0 and normalized to day 0 or normalized to NS dox.

2.10. Caspase 3 Cell Death Assay {#s0085}
--------------------------------

For caspase 3 assay, cells were lysed as described previously ([@bb0140]) and a total amount of 20 μg protein was mixed with 90 μl of assay buffer (100 mM HEPES pH 7.4, 10 mM DTT, 60 μM Ac-DEVD-AMC). Fluorescence was measured at 460 nm every 2 min for 60 min at 37 °C. Slopes of caspase activities were calculated and compared.

2.11. Mouse Maintenance, Handling and Xenografts {#s0090}
------------------------------------------------

Rag2^−/−^;γc^−/−^ mice on a BALB/C background were purchased from the local stock of the animal facility at Freiburg University Medical Center and housed in the specific pathogen-free barrier facility of the University Medical Center Freiburg in accordance with the institutional guidelines and approved by the local animal ethics committee (G-13/116). For xenograft experiments NCI-H1299 non-silencing or shRIOK1 pBabe luciferase cells were either injected on day 0 subcutaneously into the flanks (5 × 10^5^) or intravenously into the tail vain (1 × 10^5^) of Rag2 −/−,γc −/− mice, between 6 and 12 weeks of age. For Xenograft experiments, tumor growth was monitored by palpation and regular BLI and knockdown was initiated by application of doxycycline *via* the drinking water (2 mg/ml) after palpable tumors formed. For metastasis formation assays, pre-induced cells (-4d) were injected into the tail vein and cells were followed by regular BLI. Mice were sacrificed after reaching the biological endpoint and xenografts and lungs were isolated and fixed in 4% paraformaldehyde. 2 μm sections were de-paraffinized and stained with hematoxylin and eosin or RIOK1.

2.12. Histological and Immunohistochemical Analyses of Xenograft and Human Tissue Specimens {#s0095}
-------------------------------------------------------------------------------------------

Xenografts (*N* = 15) and lung metastases (*N* = 54) were formalin fixed and paraffin embedded (FFPE). Serial tissue slices of 2 μm thickness were prepared and stained for Hematoxylin and Eosin (H&E) and RIOK1 (AB_2042809; 1:1500). After one night at 56 °C incubation a heat-induced antigen retrieval was performed at 97--99 °C for a period of 40 min in pH 6.1 using Dako antigen retrieval buffer S1699. Primary antibody was incubated at room temperature for 30 min by using EnVision™ FLEX Kit K8012 (Dako, Autostainer Plus). All slides were counterstained with hematoxylin, dehydrated in ascending alcohol concentrations and covered.

### 2.12.1. Tissue Specimens {#s0100}

FFPE tissue specimens from primary non-small cell lung cancers (*N* = 30) were re-classified according to the actual WHO Classification of Tumors of the Lung, Pleura, Thymus and Heart ([@bb0385]) as follows: adenocarcinoma (AC) (*N* = 15) and squamous cell carcinoma (SCC) (*N* = 15), (see also [Table S3](#ec0020){ref-type="supplementary-material"}). Staining for RIOK1 was performed as described above.

FFPE tissue specimens from primary breast carcinomas (*N* = 22) and matched normal breast tissue (*N* = 22) were re-classified according to the actual WHO Classification of Tumors of the Breast ([@bb0205]) as follows: no special type (NST) (*N* = 14), invasive lobular (*N* = 3), mucinous (*N* = 2), tubular (*N* = 2) and medullary (*N* = 1). Additionally, hormone receptor status and Her2neu status were -- based on stained slides from routine diagnostics - re-classified according to the actual guidelines ([@bb0205]) (see also [Table S3](#ec0020){ref-type="supplementary-material"}). A tissue microarray (TMA) consisting of these 22 primary breast carcinomas and their matched normal breast tissue was stained for RIOK1 as described above. Ethical approval was obtained from the local institutional ethics committee (University of Freiburg, Ethik-Kommission, ID \#234/13).

2.13. Statistical analysis {#s0105}
--------------------------

Quantitative data are presented as mean ± SEM. Multiple group and pair-wise comparisons were performed by Mann-Whitney (two-tailed), Student *t-*test (two-tailed), paired *t*-test, two way ANOVA or Chi-square test, respectively, using GraphPad Prism 6. A *p*-value of ≤ 0.05 was considered as statistically significant.

3. Results {#s0110}
==========

3.1. Knockdown of RIOK1 in Cancer Cells Inhibits Proliferation and Impairs Growth in 3D Cell Culture {#s0115}
----------------------------------------------------------------------------------------------------

The expression of RIOK1 is hardly characterized at the mRNA and protein level in cancer. Therefore, we first analyzed *RIOK1* mRNA expression in normal and cancer tissue *in silico* using the Oncomine mRNA database ([Fig. 1](#f0005){ref-type="fig"}a). In line with previously published data on 22 primary tumors ([@bb0240]), our analysis showed that *RIOK1* mRNA levels are, compared to healthy tissue, elevated in gastric adenocarcinoma ([Fig. 1](#f0005){ref-type="fig"}b), cecal adenocarcinoma, colorectal adenoma and colorectal adenocarcinoma ([Fig. 1](#f0005){ref-type="fig"}c). Next, we evaluated the expression of all three RIO kinase members at the protein level in tumor cell lines derived from colon-, breast- and non-small cell lung cancer ([Fig. 1](#f0005){ref-type="fig"}d). We observed that the three RIO paralogues are expressed to various degrees. Based on our previous study showing a genetic collaboration between *RIOK1* and oncogenic Ras^G13E^ in *C. elegans* ([@bb0405]), we chose cancer cell lines with high RIO kinase expression and gain-of-function mutations in *NRAS* (NCI-H1299 (non-small cell lung cancer)) or *KRAS* (MDA-MB-231 (breast cancer), SW480 and HCT116 (colon cancer)) for knockdown studies to delineate the isoform-specific contributions to their transformed phenotypes. All cell lines were transduced with lentiviral vectors allowing the doxycycline (dox) inducible expression of the red fluorescent protein tRFP along with the expression of either shRNAs targeting RIOK1-3 or a non-silencing (NS) control shRNA. For RIOK1, several shRNAs were tested in NCI-H1299 and MDA-MB-231 cells resulting in different knockdown efficacies (Fig. S1a and [Table S4](#ec0025){ref-type="supplementary-material"}). Unless stated otherwise, the most effective shRNA for RIOK1 (shRIOK1_3) was chosen for the following experiments. First, we analyzed the lung- and breast cancer cell lines NCI-H1299 and MDA-MB-231, respectively. After establishing stable inducible knockdown cell lines ([Fig. 2](#f0010){ref-type="fig"}a), we investigated colony formation capacity after depletion of the individual RIOK isoforms. We observed fewer and smaller colonies in both analyzed cell lines compared to the NS control or to the isogenic non-induced controls after RIOK1 deprivation ([Fig. 2](#f0010){ref-type="fig"}b). Interestingly, knockdown of RIOK2 or RIOK3 did not yield as remarkable growth arrests ([Fig. 2](#f0010){ref-type="fig"}b), despite equally strong reduction in RIOK2 and RIOK3 expression ([Fig. 2](#f0010){ref-type="fig"}a). This demonstrates that loss of RIOK1 cannot be compensated by the other paralogs.Fig. 1RIOK1 is overexpressed in colorectal and gastric cancer. (a) Oncomine™ based mRNA expression analysis for human RIOK1 in different cancer entities comparing normal *versus* cancer tissue samples. (b and c) Oncomine™ based detailed mRNA expression analyses for gastric (b) and colorectal (c) cancer demonstrating overexpression of RIOK1 in cancer *versus* normal tissue. Significance was calculated comparing mRNA expression in normal tissue (light blue) *versus* cancerous tissue (dark blue). (d) RIO kinase protein expression analysis of different cancer cell lines using the indicated antibodies. 14-3-3 serves as loading control. Arrows indicate specific bands for RIOK1 and RIOK3.Fig. 1Fig. 2Knockdown of RIOK1 in RAS-transformed lung- and breast cancer cell lines inhibits proliferation, invasiveness and metabolism. (a) Representative Western blot analysis confirming RIOK1, RIOK2 and RIOK3 knockdown for NCI-H1299 (*N* = 4) and MDA-MB-231 cells (*N* = 2). (b) Colony formation assays of NCI-H1299 and MDA-MB-231 cells. Formed colonies were stained after 10 days and cell density was determined. Representative pictures are shown. Data is represented as mean ± SEM with \*\*\* for *p* \< 0.001 and \*\*\*\* for *p* \< 0.0001 by ordinary two-way ANOVA (Dunnett (H1299) and Tukey (MDA-MB-231)) compared to non-sil. dox. NCI-H1299 *N* = 6 for NS and shRIOK1, *N* = 2 for shRIOK2 and 3. MDA-MB-231 *N* = 4 for NS and shRIOK1, *N* = 1 for shRIOK2 and 3. (c) NCI-H1299 and MDA-MB-231 cells were seeded in 2% Matrigel and grown for up to 14 days. Scale bars: 200 μm. (d) MTT assay sequentially measured for 4 days for NCI-H1299 and MDA-MB-231 cells. Data is represented as mean ± SEM by multiple *t*-test; *N* = 3, each. (See also Fig. S1).Fig. 2

As the growth behavior of carcinoma cells can strongly differ between conventional tissue culture and 3D matrix growth ([@bb0065], [@bb0145]), we assessed the effects of RIOK depletion in three-dimensional (3D) matrices. Again, reduced growth was only observed upon RIOK1 deprivation ([Fig. 2](#f0010){ref-type="fig"}c). RIOK1 depleted spheres displayed rounder shapes, less filopodia-like structures and protrusions.

Next, we investigated the metabolic activity of NCI-H1299 and MDA-MB-231 cells upon loss of RIOK1 by sequential MTT measurements over four days ([Fig. 2](#f0010){ref-type="fig"}d). From day three onwards, RIOK1 deficient cells displayed a significantly reduced metabolic activity compared to the NS control cells or non-induced cells. Importantly, the ability to reduce proliferation in conventional and 3D matrix culture as well as the metabolic activity of NCI-H1299 and MDA-MB231 cells correlated with the knockdown efficacies of the distinct RIOK1 shRNAs (Fig. S1b--d). As we observed only an insignificant increase in caspase-3 activity upon RIOK1 knockdown (Fig. S1e), we exclude cell death as main driver for the observed phenotypes.

Next, we analyzed the cellular response of the K-Ras-driven colorectal cancer cell lines HCT116 and SW480 upon RIOK1 depletion ([Fig. 3](#f0015){ref-type="fig"}). After having established inducible shRIOK1 and control cell lines for SW480 cells ([Fig. 3](#f0015){ref-type="fig"}a), we analyzed their proliferation capacity in 2D and 3D culture after RIOK1 depletion. As shown in [Fig. 3](#f0015){ref-type="fig"}b, SW480 cells formed fewer colonies in conventional culture and were impaired in 3D matrix growth ([Fig. 3](#f0015){ref-type="fig"}c), although the growth arrest appeared not as profound as observed in MDA-MB-231 or NCI-H1299 cells. Metabolic activity was also impaired upon RIOK1 knockdown ([Fig. 3](#f0015){ref-type="fig"}d). Similar results were obtained for HCT116 cells ([Fig. 3](#f0015){ref-type="fig"}e). Again, cell growth appeared more strongly impaired in conventional culture ([Fig. 3](#f0015){ref-type="fig"}f) as compared to 3D matrix growth ([Fig. 3](#f0015){ref-type="fig"}g). Accordingly, cell metabolic activity was again reduced upon RIOK1 depletion ([Fig. 3](#f0015){ref-type="fig"}h). Similar to MDA-MB-231 and NCI-H1299 cells, knockdown with shRIOK1 knockdown construct \#3 led to stronger growth arrest, which again correlated with the knockdown efficacy (Figs. S1 and 3e--h). It should be noted that, while our study was in progress, [@bb0265] also observed impaired proliferation of HCT116 cells in 2D culture upon RIOK1 knockdown with shRNA constructs unrelated to ours in terms of target sequence and vector design.Fig. 3Knockdown of RIOK1 in RAS-transformed colon cancer cell lines inhibits proliferation and metabolism. (a) Representative RIOK1 knockdown Western blot analysis for SW480 cells (*N* = 3). (b) Colony formation assays of SW480 cells. Formed colonies were stained after 7 days and cell density was determined. Representative pictures are shown. Data is represented as mean ± SEM with \*\* for *p* \< 0.01 by ordinary two-way ANOVA (Tukey) compared to non-sil. dox. *N* = 3. (c) SW480 cells were seeded in 2% Matrigel and grown for 13 days. Scale bar: 200 μm. (d) MTT assay measured on day 3 for SW480 cells. Data is represented as mean ± SEM; *N* = 2. (e) RIOK1 knockdown Western blot analysis for HCT116 cells (*N* = 1). (f) Colony formation assays of HCT116 cells. Formed colonies were stained after 10 days and cell density was determined. Representative pictures are shown. Data is represented as mean ± SEM with \* for *p* \< 0.05 by ordinary two-way ANOVA (Dunnett) compared to non-sil. dox; *N* = 4. (g) HCT116 cells were seeded in 2% Matrigel and grown for 18 days. Scale bars: 200 μm. (h) MTT assay measured on indicated timepoints and normalized to day 0 for HCT116 cells. Data is represented as mean ± SEM with \* for *p* \< 0.05 by two-way ANOVA (Tukey); *N* = 3.Fig. 3

The severe effect of RIOK1 depletion could reflect a strong necessity for this atypical kinase in fundamental cellular processes rather than a specific requirement in RAS-mediated transformation. Therefore, we analyzed the influence of RIO kinase knockdown on well-differentiated adenocarcinoma cell line Caco-2, the BRAF^V600E^ and PI3KCA^H1047R^-driven colorectal cancer cell line RKO and the Bcr-Abl driven leukemia cell line K562 (Fig. S2). Knockdown of RIOK1 in Caco-2 cells (Fig. S2a) did neither affect colony formation (Fig. S2b) nor growth in three-dimensional matrix (Fig. S2c) and metabolic activity (Fig. S2d). Likewise, knockdown of RIOK1 did not inhibit 3D growth of RKO cells (Fig. S2e and f) and did not alter cell viability of the Bcr-Abl-driven K562 leukemia cell line (Fig. S2g and h). This indicates that RIOK1 depletion is not always cytostatic.

So far, we have observed exclusively strong effects of RIOK1 depletion in established cancer cell lines carrying an endogenous *RAS* mutation. Therefore, we were interested to investigate the effects of RIOK1 depletion in an isogenic system in which oncogenic RAS was not expressed *a priori*, but was acutely introduced only a few passages before RIOK1 depletion. To this end, we turned to the non-tumorigenic human mammary epithelial cell line MCF-10A, which lacks mutations in *RAS* (or its effectors) and has been spontaneously immortalized by *MYC* amplification and loss of p16^INK4^ and p14^ARF^ ([@bb0065]). In 3D culture, these cells form so-called acini in a well-defined morphogenetic process that integrates multiple biological processes in a coordinated spatio-temporal fashion. Potent oncogenes such as RAS mutants perturb acinar morphogenesis by multiple processes ([@bb0145], [@bb0235]). Therefore, we infected MCF-10A cells with pMIG retroviral expression vectors encoding GFP, either singly or in combination with KRAS^G12V^ ([Fig. 4](#f0020){ref-type="fig"}a). As shown in [Fig. 4](#f0020){ref-type="fig"}b and c, overexpression of KRAS^G12V^ in MCF-10A cells induced growth arrest in conventional cell culture. Knockdown of RIOK1 reduced the growth of empty vector and KRAS^G12V^ expressing cells, whereas the NS construct had no influence on colony growth. Importantly, this growth arrest upon RIOK1 loss was stronger in KRAS^G12V^ expressing cells. Related to this finding, cell metabolic activity of RIOK1 deficient cells was reduced in empty vector and KRAS^G12V^ expressing cells on day 3 and 4 after seeding, too ([Fig. 4](#f0020){ref-type="fig"}d). When cultured in 3D matrix, MCF-10A KRAS^G12V^ high expressing cells formed colonies with invasive protrusions ([Figs. 4](#f0020){ref-type="fig"}e and S3a, black arrows). A similar invasive 3D phenotype has been described for oncogenic H-Ras ([@bb0235]). In contrast to conventional growth, knockdown of RIOK1 did neither impair the growth nor the overall structure of the formed acini in empty vector expressing cells ([Figs. 4](#f0020){ref-type="fig"}e 1st and 3rd panel, S3a). Importantly and in line with our results in NCI-H1299 and MDA-MB-231 cells ([Fig. 2](#f0010){ref-type="fig"}c), RIOK1 deficiency prevented the formation of invasive protrusions in KRAS^G12V^ expressing MCF-10A cells ([Figs. 4](#f0020){ref-type="fig"}e and S3a, white arrows). Likewise, the typical loss of contact inhibition induced by oncogenic RAS was partially reverted by the loss of RIOK1 expression ([Fig. 4](#f0020){ref-type="fig"}e, 2nd and 4th panel). We further analyzed MCF-10A acini by E-Cadherin staining (Fig. S3b and S3c), a marker often used to assess the acinar structure of MCF-10A cells ([@bb0145]). Knockdown of neither RIOK1, 2 nor 3 did alter E-Cadherin expression or MCF-10A acini formation compared to non-silencing expressing spheres (Fig. S3c).Fig. 4KRAS-induced transformation of epithelial MCF-10A can be partially prevented by knockdown of RIOK1. (a) RIOK1 knockdown Western blot analysis for MCF-10A KRAS cells (*N* = 1). (b and c) Colony formation assays of MCF-10A KRAS cells. Formed colonies were stained after 14 days and cell density was determined. Representative pictures are shown. Data is represented as mean ± SEM with \*\*\*\* for *p* \< 0.0001, \*\*\* for *p* \< 0.001, \*\* for *p* \< 0.01 and \* for *p* \< 0.05 by ordinary two-way ANOVA (Tukey); *N* = 3. (d) MTT assay measured on indicated timepoints for MCF-10A KRAS cells. Data is represented as mean ± SEM with \*\*\* for *p* \< 0.001, \*\* for *p* \< 0.01 and \* for *p* \< 0.05 by two-way ANOVA (Tukey); *N* = 3. (e) MCF-10A KRAS cells were seeded in 2% Matrigel and grown for 28 days. Scale bars: 200 μm. Black arrows indicate invasive protrusion formed in the GFP/KRAS^G12V^ transformed cells. Note that these are lost upon RIOK1 knockdown (white arrows) (See also Fig. S3).Fig. 4

In summary, our data demonstrates that RIOK1 knockdown reverts the strong 2D and 3D growth and invasion phenotypes of four distinct RAS-driven carcinoma cell lines derived from three tumor entities as well as of MCF-10A cells transformed by KRAS^G12V^. This suggests that the growth and invasion promoting function of RIOK1 is of particular relevance for *RAS* mutant cells.

3.2. A Mass-spectrometric Approach Identifies Effector Proteins of RIOK1 {#s0120}
------------------------------------------------------------------------

Besides its important role in ribosomal biogenesis and as substrate recruiting protein of the PRMT5 complex ([@bb0125]), no cancer-related molecular functions are known for mammalian RIOK1. Therefore, we used a SILAC-based mass-spectrometric (MS) approach ([Fig. 5](#f0025){ref-type="fig"}a and [Table S1](#ec0010){ref-type="supplementary-material"}) and an antibody array ([Table S2](#ec0015){ref-type="supplementary-material"}) to gain more insights into the protein network controlled by RIOK1 in NCI-H1299. To this end, the proteome of RIOK1-expressing cells was compared to that of RIOK1 depleted cells. We quantified \> 2800 proteins and identified significant changes based on SILAC ratio distributions ([Fig. 5](#f0025){ref-type="fig"}b; significance B, permutation based FDR \< 0.05) ([@bb0045]). Significantly deregulated proteins were linked to known interactions using STRING DB and respective protein networks were generated ([Fig. 5](#f0025){ref-type="fig"}c) ([@bb0115]). Upon RIOK1 knockdown, several known pre-40S ribosomal subunit proteins were upregulated ([@bb0390], [@bb0425]), including RIOK2 ([Fig. 5](#f0025){ref-type="fig"}b and c). Down-regulated proteins were associated with cell cycle (Cyclin B1, Anillin, TYMS, UBE2S) or metabolic activity (G0S2, SCD-1, ASNS). Interestingly, the oncogene product Metadherin (MTDH), which promotes AKT- and NF-κB signaling and metastasis formation ([@bb0080], [@bb0130], [@bb0165], [@bb0225], [@bb0345]), was reduced in expression. Analysis of proteins with altered posttranslational modified status upon RIOK1 knockdown showed an increased phosphorylation of Stathmin1 (S25/38) and La-related protein1 (LARP1; S774). Stathmin1 promotes tumor growth and metastases by microtubule-dependent and independent mechanisms and is required for invasive growth in 3D neuroblastoma models ([@bb0105]). LARP1 contributes to cell cycle initiation and progression ([@bb0035]). In conclusion, we show that depletion of RIOK1 affects the expression and phosphorylation status of several proteins involved in ribosomal biogenesis, cell cycle progression, metabolic activity, NF-κB signaling and metastases.Fig. 5SILAC-based mass-spectrometric approach and validation of RIOK1 effector proteins. (a) NCI-H1299 shRIOK1 cells were labeled by SILAC and induced or left untreated 6 days prior to lysis. Lysates were mixed and analyzed by LC-MS/MS. (b) SILAC-based fold-changes of up- and down-regulated proteins upon RIOK1 knockdown are shown. Red rhombuses indicate significantly changed proteins upon knockdown (significance B, permutation based FDR \< 0.05). (c) Protein-protein interaction network for significantly regulated proteins upon Riok1 depletion. (d) Representative Western blot analysis and quantifications of NCI-H1299 cells for cell cycle proteins and (e) RIOK1 effector proteins *N* = 4; \*\*\* for *p* \< 0.001; \*\* for *p* \< 0.01 and \* for *p* \< 0.05; unpaired two-tailed *t*-test (mean ± SEM). (See also Figs. S4 and S5).Fig. 5

3.3. RIOK1 Knockdown Blocks Cell Cycle Progression and Impairs Cell Viability {#s0125}
-----------------------------------------------------------------------------

To validate the MS data, we analyzed the abundance of the identified RIOK1 effector proteins in our cell line models. Starting with NCI-H1299 cells, we first confirmed the role of mammalian RIOK1 in cell cycle progression. RIOK1 knockdown resulted in decreased expression of Cyclin A2, Cyclin B1, Aurora kinases A and B as well as in a clear decrease of CDK1 phosphorylation (Y15) ([Fig. 5](#f0025){ref-type="fig"}d). Furthermore, we confirmed the MS predicted increase of RIOK2 expression upon RIOK1 knockdown ([Fig. 5](#f0025){ref-type="fig"}e), which was accompanied by a robust electrophoretic mobility shift. In addition to decreased MTDH levels, we also noticed a significant downregulation of RIOK3 expression. The expression of Stathmin1 was not altered, but its phosphorylation on Ser38, a site recently shown to be important for breast cancer cell invasion ([@bb0195], [@bb0200]), was clearly reduced ([Fig. 5](#f0025){ref-type="fig"}e).

Next, we confirmed the influence of RIOK1 knockdown on its identified effectors in our other cellular systems (Figs. S4 and S5). We detected the increased expression and electrophoretic shift for RIOK2 and the decreased expression for RIOK3 upon RIOK1 knockdown in all cell lines except for K562 and MCF-10A KRAS^G12V^ cells. This suggests that the three RIOK isoforms regulate each other, or are controlled in their expression due to their essential consecutive roles in ribosomal biogenesis.

For the other effectors, we observed a segregation between RAS-driven and non-RAS-driven cancer cells on the one hand and between colorectal and non-colorectal cells on the other hand. Whereas Cyclin B1 was reduced in expression in most cell lines except for SW480, MCF-10A and K562 cells, Cyclin A2 was only reduced in its expression in MDA-MB-231 cells. Phosphorylation of CDK1 (Y15), Stathmin1 (S38) and MTDH expression were clearly reduced in MDA-MB-231 and MCF-10A KRAS^G12V^ cells, which was not the case for the other cell lines. Most importantly, RIOK1 knockdown in MCF-10A empty vector control cells did not provoke the expression changes observed in MCF-10A KRAS^G12V^ cells, emphasizing that RIOK1 expression is critical for KRAS^G12V^ signaling. Although all RAS-driven cell lines reacted upon RIOK1 knockdown with decreased growth and cell metabolism ([Fig. 2](#f0010){ref-type="fig"}, [Fig. 3](#f0015){ref-type="fig"}, [Fig. 4](#f0020){ref-type="fig"}), only NCI-H1299, MDA-MB-231 and MCF-10A KRAS^G12V^ cells share regulation of identified RIOK1 effectors on the protein level. This result may indicate different cellular functions for RIOK1 in colorectal cancer cell lines, compared to lung- and breast cancer cells.

3.4. Invasive Protrusions Rely on RIOK1 Expression and NF-κB Activity {#s0130}
---------------------------------------------------------------------

It was previously shown that MTDH is a positive regulator of the NF-κB pathway in various cancer entities by being an IKK substrate and promoter of phosphorylation-dependent IκB degradation ([@bb0005], [@bb0185], [@bb0355]). As MTDH expression decreases upon RIOK1 depletion and because oncogenic RAS promotes NF-κB activity ([@bb0020]), we asked whether RIOK1 depletion impairs NF-κB signaling. First, we detected a diminished basal NF-κB activity upon RIOK1 knockdown in NCI-H1299 and MDA-MB-231 cells by using a luciferase reporter for transcriptionally competent NF-κB ([Fig. 6](#f0030){ref-type="fig"}a). To further narrow down at which step RIOK1 depletion affects the NF-κB pathway, we co-expressed different IKK2 constructs together with the NF-κB luciferase reporter in the NCI-H1299 system ([Fig. 6](#f0030){ref-type="fig"}b and c). Expression of wildtype IKK2 neither increased basal levels of NF-κB activity nor was able to rescue the reduction in pathway activity by RIOK1 depletion. Expression of the kinase inactive IKK2^K44M^ mutant reduced pathway activity under all conditions, whereas the expression of IKK2^S177/181E^, a constitutively active mutant, increased pathway activation in all cell lines. Still, IKK2^S177/181E^ was not able to augment pathway activity in RIOK1 deficient cells to the same extent as in the non-induced culture or dox-treated NS cells. To further address at which level RIOK1 depletion impairs NF-κB activity, we stimulated NCI-H1299 RIOK1 knockdown and NS control cells with TNFα in the presence or absence of Bay 11-7082, an IKK inhibitor ([@bb0370]), and analyzed the abundance of key pathway components in the cyto- and nucleoplasm ([Fig. 6](#f0030){ref-type="fig"}d and e). Under basal conditions, we observed a trend (*p* = 0.089) for increased levels of IκBα, the negative regulator of NF-κB signaling upon RIOK1 depletion ([Fig. 6](#f0030){ref-type="fig"}d, lane 2). Moreover, RIOK1 deficient cells displayed significantly less phosphorylation of IkBa at S32 compared to the control cells ([Fig. 6](#f0030){ref-type="fig"}e lane 6). These data suggest impaired IkBa degradation in RIOK1 depleted cells. In line with this, RIOK1 depleted cells displayed less nuclear p65/NF-κB ([Fig. 6](#f0030){ref-type="fig"}d, lane 10). As expected, Bay 11-7082 stabilized IκBα expression under both basal and TNFα stimulated conditions and strongly impaired p65 phosphorylation and nuclear accumulation ([Fig. 6](#f0030){ref-type="fig"}d, lanes 12--16). However, RIOK1 abundance had no influence on the TNFα-induced activation of the pathway, suggesting that the strong TNFα signal also activated RIOK1 independent pathways to IκBα phosphorylation. The impaired pathway activation by Bay 11-7082 was also not further enhanced by combination with RIOK1 knockdown. Thus, in line with the identification of MTDH as an IKK complex component and substrate ([@bb0185]), we place the contribution of RIOK1 to NF-κB signaling upstream of IκBα degradation, probably parallel to the IKK complex.Fig. 6RIOK1 knockdown impairs NF-κB signaling. (a) NCI-H1299 and MDA-MB-231 NF-κB luciferase reporter assay measured after 48 h normalized to NS dox; data is represented as mean ± SEM with \* for *p* \< 0.05 by two-way ANOVA (Tukey); *N* = 3. (b and c) Induced NCI-H1299 non-silencing (NS) or shRIOK1 (R1) cells were transfected with NF-κB luciferase reporter plasmids and IKK2 coding plasmids (empty vector (e.V.), wildtype (WT), kinase dead (KD) or constitutive active (CA)) and lyzed after 48 h. Expression IKK2 was confirmed by probing lysates for Flag-tagged IKK (b) and NF-κB activity was determined (c). Data is represented by mean ± SEM with \*\*\* for *p* \< 0.001; \*\* for *p* \< 0.01 and \* for *p* \< 0.05 by two-way ANOVA (Tukey); *N* = 3. (d) Induced NCI-H1299 non-silencing (NS) or shRIOK1 (R1) cells were treated with Bay 11-7082 (10 μM) or DMSO for 1 h followed by a 15 min stimulation with TNFα (10 ng/ml). Cell lysates for cytosolic (C) and nuclear (N) fractions were analyzed with the indicated antibodies. 14-3-3 and Lamin B were used as loading controls for cytosolic and nuclear fractions, respectively. Please note the panels for pP65, P65 and RIOK1 are composed of two exposures from the same gels. This was necessary as the abundance and consequently the signals of these proteins strongly differ between cyto- and nucleoplasm. Quantification of Western blot analysis shown in d and e is depicted below. (mean ± SEM, *N* = 3; unpaired two-tailed *t*-test). (e) NCI-H1299 non-silencing (NS) or shRIOK1 (R1) cells were stimulated with TNFα (10 ng/ml) and cytosolic lysate fractions were probed for phosphorylated IκBα N = 3. (f) NCI-H1299 non-silencing or shRIOK1 cells were seeded in 2% Matrigel and allowed to grow for 3 days before they were treated with DMSO or Bay 11-7082 (10 μM) for 12 days. Scale bar: 200 μm. (See also Figs. S6 and S7).Fig. 6

Next, we assessed the effect of NF-κB pathway inhibition on the invasive phenotype of NCI-H1299 cells. In 3D cultures of NCI-H1299 cells, the constant inhibition of the NF-κB pathway resulted in a similar phenotype as provoked by RIOK1 knockdown with spheres displaying a smaller diameter and a reduction of invasive protrusions ([Fig. 6](#f0030){ref-type="fig"}f). In contrast to the signaling analysis, this phenotype was further enhanced by combination of Bay 11-7082 treatment with RIOK1 knockdown.

RIOK3 has been implicated in the regulation of actin filaments of breast cancer cells, especially in the context of hypoxic regulation ([@bb0360]). We therefore analyzed protrusion formation for the NCI-H1299 cells grown in 3D matrix displayed in [Fig. 6](#f0030){ref-type="fig"}f. RIOK1 deficient cells showed reduced F-Actin expression and a localization of F-Actin at the cell membranes (Figs. S6 and S7). In contrast, NS and non-induced shRIOK1 cells formed protrusions with branching filopodia-like structures with high levels of F-actin throughout the cell (Figs. S6 and S7). Furthermore, RIOK1 depletion as well as Bay 11-7082 largely reduced the amount of filopodia-like structures. Taken together, these data suggest that RIOK1 activates NF-κB signaling at the level of the IKK complex and thereby augments the invasive growth behavior of NCI-H1299 cells.

3.5. RIOK1 Promotes the Formation of Metastases to the Lung *In Vivo* {#s0135}
---------------------------------------------------------------------

Next, we analyzed the requirement of RIOK1 for invasive cell behavior *in vivo*. In a pilot xenograft experiment, we investigated subcutaneous tumor growth of NCI-H1299 cells. Non-induced NS and shRIOK1 cells were injected into the flanks of immunocompromised Rag2^−/−^ γc^−/−^ mice and knockdown of RIOK1 was induced once palpable tumors arose. The growth of the inoculated subcutaneous tumors did not differ between NCI-H1299 RIOK1 knockdown and NS control cells, although histological analyses revealed less metastatic burden in the lung (Fig. S8a--c). Western blot analysis confirmed the sustained knockdown of RIOK1 in isolated xenografts (Fig. S8d). Histological staining with H&E and a human specific RIOK1 antibody (Fig. S8e) were performed with NCI-H1299 xenografts. This showed that the xenografts formed by NS cells were characterized by increased cellularity and presence of mitoses/metaphases as compared to those derived from induced NCI-H1299 shRIOK1 cells (Fig. S8f).

To investigate the metastatic potential of NCI-H1299 cells with or without RIOK1 expression in mice in more detail, the cells were labeled by luciferase expression and injected either into the flanks or into the tail vein of Rag2^−/−^;γc^−/−^ mice. Luciferase positive NCI-H1299 lung cancer cells were followed by consecutive bioluminescence imaging (BLI). In the case of subcutaneous (s.c.) injection, knockdown of RIOK1 was induced by administration of dox *via* the drinking water once xenografts were detectable for both cell lines in all mice. BLI and tRFP signal analyses did not show any difference in primary tumor growth (Fig. S9a--c). Moreover, the weight of the injected mice was not altered between the groups (Fig. S9d). These observations are in line with our pilot study (Fig. S8). Strikingly, RFP fluorescence analyses of the isolated lungs reported metastasis formation only for NCI-H1299 NS control cell injected mice (Fig. S9e and f). Again, Western blot analysis of the formed xenografts confirmed the sustained knockdown in the shRIOK1 tumors (Fig. S9g).

Next, we conducted tail vein injection of induced NCI-H1299 shRIOK1 and NS control cells to answer the question whether RIOK1 expression is necessary to enable circulating cells to colonize distinct organs ([Fig. 7](#f0035){ref-type="fig"}). Indeed, NCI-H1299 cells expressing the NS shRNA- or the non-induced shRIOK1 construct effectively colonized to the lungs as analyzed by BLI and RFP expression measurements of living animals and isolated lungs ([Fig. 7](#f0035){ref-type="fig"}a and b). However, no BLI expressing cells were detectable in mice injected with RIOK1 deficient cells. Analysis of the co-expressed RFP confirmed colony formation in the lungs of mice inoculated with NCI-H1299 NS but not of induced RIOK1 knockdown cells ([Fig. 7](#f0035){ref-type="fig"}b).Fig. 7RIOK1 enables lung colonization. (a) Luciferase expressing NCI-H1299 non-silencing and shRIOK1 cells were injected i.v. in mice and tumor growth was followed using BLI for up to 98 days. (b) *Ex vivo* fluorescence imaging of isolated lungs on day 100. *N* = 2. Doxycycline (2 mg/ml) was administered constantly *via* the drinking water. (c) Representative histological (H&E) and immunohistochemical (RIOK1) staining of the isolated lungs from this experiment and from s.c. injections (Figs. S8 and S9). Arrows point out RIOK1 positive tumor cells. Scale bar upper panel: 200 μm. Scale bar middle and lower panel: 20 μm. (d) Upon s.c. injection (left), NCI-H1299 NS cells preferentially formed nodules of tumor cells (score 2), whereas shRIOK1 cells formed smaller colonies consisting of single cells (score 1). In the case of i.v. injection (right), induced NCI-H1299 shRIOK1 failed to form colonies (score 0), whereas NCI-H1299 NS and non-induced shRIOK1 cells massively infiltrated the lungs of recipient mice (score 3). *N* = 7 for NS and *N* = 8 for shRIOK1 for s.c. injections. *N* = 15 for NS, *N* = 8 shRIOK1 no dox and *N* = 16 for shRIOK1 dox for i.v. injection; Chi-square test. (See also Figs. S8 and S9).Fig. 7

Histological analysis of the lungs confirmed that those cells forming the metastatic spots highly expressed RIOK1 ([Fig. 7](#f0035){ref-type="fig"}c). Furthermore, as this antibody recognizes an epitope only present in human RIOK1, it can be also used to distinguish human tumor cells from murine stroma.

Scoring of the isolated lungs of all *in vivo* experiments demonstrated that, upon s.c. injection, NCI-H1299 NS control cells preferentially formed metastases appearing as nodules of tumor cells (score 2; 10--20 cells), whereas shRIOK1 cells formed metastases consisting of single or few cells (score 1) ([Fig. 7](#f0035){ref-type="fig"}d, left quantification). For i.v. injection, NCI-H1299 shRIOK1 cells failed to colonize to the lungs in 15 out of 16 dox-treated recipient mice, while NCI-H1299 NS control and non-induced shRIOK1 cells formed massive colonies (score 3) in 14 out of 15 and 7 out of 8 animals, respectively ([Fig. 7](#f0035){ref-type="fig"}d, right quantification). Taken together, these data suggest that RIOK1 depleted cells are impaired in colonization and implicate RIOK1 as a potential therapeutic target for metastasis prevention.

3.6. RIOK1 is Overexpressed in Human Lung- and Breast Cancer Specimens {#s0140}
----------------------------------------------------------------------

Our preclinical findings encouraged us to analyze primary lung and breast cancer human tissue specimens or RIOK1 expression. Indeed, in a group of 30 lung cancer tissue specimens, we detected higher levels of RIOK1 expression in the subtypes of squamous cell carcinoma (SCC) (*N* = 15), compared to a heterogeneous expression observed in the adenocarcinoma subtypes (*N* = 15) ([Fig. 8](#f0040){ref-type="fig"}a and b).Fig. 8RIOK1 protein expression in human lung and breast carcinomas. (a) Representative lung adenocarcinomas (AC) and lung squamous cell carcinomas (SCC). RIOK1 protein expression was scored as follows: score 0 (no expression), score 1 (low expression) and score 2 (high expression). (b) Quantification of immunohistochemical evaluation according to the histological subtypes; *N* = 15 per group. (c) Representative histological (H&E) and immunohistochemical (RIOK1) staining of the lobular or the NST (no special type) subtype. (d) Comparison of RIOK1 protein expression in normal breast epithelium and breast carcinomas. *N* = 22 tumor and normal matched pairs. (e) RIOK1 protein expression in breast carcinomas is linked to histologic grading. (f and g) RIOK1 expression in breast carcinomas is inversely correlated to estrogen (ER) and progesterone (PR) receptor expression, but is not associated with HER2 expression. All images were taken with 20 × magnification. AC Adenocarcinoma, SCC squamous cell carcinoma. Data in b, d--g are represented as % of analyzed cases and statistically analyzed by Chi-square test.Fig. 8

Next, we scored RIOK1 expression in a collective of 22 breast carcinoma samples (WHO reclassified in [Table S3](#ec0020){ref-type="supplementary-material"}) with matched non-neoplastic tissue. Expression of different histological subtypes was heterogeneous ([Fig. 8](#f0040){ref-type="fig"}c), whereas RIOK1 was expressed in a comparable ratio between non-neoplastic and tumor tissue ([Fig. 8](#f0040){ref-type="fig"}d), which is in accordance to our initial *in silico* analysis ([Fig. 1](#f0005){ref-type="fig"}a). When analyzing RIOK1 expression and tumor grading independent of the histological subtypes, we observed stronger RIOK1 expression in less differentiated grade 3 tumors ([Fig. 8](#f0040){ref-type="fig"}e). Important predictive markers for targeted therapies in breast carcinomas are hormone receptor status and HER2 expression. Therefore, we correlated the expression of the estrogen and progesterone receptor with the expression of RIOK1. This analysis showed an inverse correlation between hormone receptor status and RIOK1 expression ([Fig. 8](#f0040){ref-type="fig"}f), while the proportion of RIOK1 high and low expressing tumors was comparable between HER2 negative and positive tumors ([Fig. 8](#f0040){ref-type="fig"}g).

3.7. RIOK1 Knockdown Susceptibility Does Not Necessarily Correlate With *MTAP* Expression {#s0145}
-----------------------------------------------------------------------------------------

So far we have identified RIOK1 as a critical contributing factor to oncogenic RAS signaling in three distinct cancer entities using cell lines from lung-, triple-negative breast- and colorectal cancer ([Fig. 9](#f0045){ref-type="fig"}a). However, it is likely that RIOK1 dependence is not only mediated by the *RAS* mutational status. Interestingly, three recent publications identified depletion of RIOK1, or its interaction partner PRMT5, as a critical prerequisite for synthetic lethal constellations triggered by loss of the *MTAP* locus ([@bb0190], [@bb0265], [@bb0270]). Marjon et al. and Mavrakis et al. established this requirement for RIOK1 expression in KRAS^G13D^ mutant HCT116 colorectal and KRAS^G12C^ mutant MiaPaCa2 pancreatic cancer cells, respectively, although the *RAS* mutational status was not considered in the interpretation of their data. Indeed, Marjon et al. show that RIOK1 depletion, using shRNA constructs distinct from ours, also reduces colony growth of HCT116 cells by 40%, which is further reduced to 20% in the isogenic *MTAP* −/− line. These data led to a model in which MTAP deficiency leads to the accumulation of its substrate methylthioadenosine, which represses the PRMT5/RIOK1 complex and pro-proliferative and biosynthetic pathways that are positively regulated by PRMT5 ([@bb0265]). Consequently, we analyzed the *MTAP* status for our cell lines ([Fig. 9](#f0045){ref-type="fig"}b). Interestingly, NCI-H1299 cells express MTAP, whereas MDA-MB-231 do not ([Fig. 9](#f0045){ref-type="fig"}b and c). This finding correlates well with the observed effects of RIOK1 depletion in these cells as MDA-MB-231 responded with an even stronger growth arrest as compared to the NCI-H1299 cells. Furthermore, we observed MTAP expression in all analyzed colorectal cancer cell lines, which could explain the less severe effects observed in SW480, HCT116 and RKO cells upon RIOK1 knockdown. In our two epithelial cell lines Caco-2 (MTAP proficient) and MCF-10A (MTAP deficient), the effects of the RIOK1 knockdown correlated again with the MTAP status. Whereas Caco-2 cells were not susceptible to RIOK1 knockdown, MCF-10A cells responded partially to the knockdown in conventional culture but not in the more physiological setting of 3D matrix culture. Finally, the CML cell line K562 (MTAP deficient) did not respond to RIOK1 knockdown. Thus, our data identify RIOK1 as a potential therapeutic target in the context of *RAS* mutations, in particular but not exclusively in the context of *MTAP* deficiency. Further studies will address the question whether MTAP (or PRMT5) depletion in combination with RIOK1 deficiency (and oncogenic RAS signaling) further reduces cellular fitness.Fig. 9Heatmap of cellular behavior upon RIOK1 knockdown and MTAP status analysis. (a) Scoring determined based on densitometry measurements as follows: strongly decreased: reduction in expression ≥ 40%; decreased: reduction in expression ≥ 20%; increased: augmented expression ≥ 50%; n.d. not determined. (b) Western blot analysis of MTAP expression in different cell lines of colon-, breast- and und lung cancer (*N* = 1). (c) RIOK1 knockdown does not influence MTAP expression in NCI-H1299 and MB-MB-231 cells (*N* = 1).Fig. 9

4. Discussion {#s0150}
=============

In this study, we identified the under-researched atypical kinase RIOK1 as a critical contributor to the transformed phenotypes of RAS-driven cell lines from lung, triple-negative breast and colorectal cancer. In contrast, the growth of cell lines lacking *RAS* mutations, such as the epithelial Caco-2 cell line, the BRAF^V600E^ and PI3K^H1047R^ driven RKO cell line or K562 cells, driven by the potent Bcr-Abl oncoprotein, were not or only partially affected by RIOK1 knockdown. In spontaneously immortalized MCF-10A mammary epithelial cells with or without ectopic KRAS^G12V^ expression, knockdown of RIOK1 partially reverted invasive growth in 3D culture. Thus, our data demonstrating a requirement for RIOK1 in the proliferation and invasion of carcinoma cells significantly extend the findings by Luo et al., who first observed RIOK1 as a hit in a synthetic lethal proliferation shRNA screen in *KRAS*^G13D^ mutant DLD-1 colorectal cancer cells ([@bb0250]). Based on its enzymatic character, Luo et al. already suggested that further validation efforts will be required to assess the addiction of *RAS* mutant cells to these genes and to evaluate their utility as drug targets in cancer cells ([@bb0250]). Further validation of RIOK1 was not conducted in this study. Since then, however, the critical role of RIOK1 in *RAS* mutant cells has been, in addition to the data presented in our study, further supported by the following screens. While our paper was under revision, Kiessling et al. published a CRISPR/Cas9 screen in cell lines driven by either mutant EGFR or NRAS ([@bb0175]). Interestingly, only the growth of the latter was affected by RIOK1 knock-out. In that regard, we used cBioPortal to investigate whether RIOK1 overexpression co-occurs with *HRAS* or *KRAS* alterations in breast and lung cancer. Although this program identified a co-occurrence for some constellations in breast cancer (Fig. S10), we suggest that this aspect needs to be validated in future studies that not only include the genetic alterations of *RAS* genes but also of their modifiers such as RAS inactivating GTPase activating proteins that are often lost in breast cancer by (*epi*)genomic events ([@bb0275], [@bb0310]).

Likewise, data in the Achilles project database demonstrate that the "essentiality" for RIOK1 expression differs between the various cell lines and that many *RAS* mutant cell lines are more affected in this independent CRISPR/Cas9 screen (Fig. S11) (<https://portals.broadinstitute.org/achilles>). Thus, both CRISPR/Cas9 based data sets further support our concept with an shRNA independent approach that RAS-driven tumor cells are particularly reliant on RIOK1 expression. Moreover, these data sets and our study suggest that RIOK1 depletion is not generally toxic to cells, but might represent an *Achilles heel* specifically for RAS-driven cancers. Indeed, knockdown studies on this highly conserved atypical kinase in *C. elegans* show that worms reach adulthood, although they display defects in their reproductive system ([@bb0280], [@bb0405]). Still, as the effects of RIOK1 deficiency in mammals remain unknown so far, these data suggest that many cell types do not rely on full RIOK1 expression or activity for survival or differentiation.

So far, RIO kinases have been mostly studied in yeast, but the few studies addressing their function in mammalian cells identified an important role of all three family members in ribosomal biogenesis ([@bb0025], [@bb0095], [@bb0100], [@bb0395], [@bb0425]). Furthermore, RIOK1 has been implicated in cell cycle progression of the yeast *Saccharomyces cerevisiae* and to promote either S-phase or G2/M transition ([@bb0015]). By our expression analysis of cell cycle regulators in NCI-H1299 cells, we provide confirmation that RIOK1 critically contributes to proliferation in mammalian cells as well. This analysis also indicates an arrest or significant delay at the G2/M checkpoint. Importantly, the strong requirement for RIOK1 for proliferation was only visible in *RAS* mutant cell lines, which identifies RIOK1 as potential vulnerability of RAS-driven tumors. As we could not observe a clear effect of RIOK1 depletion on classical RAS-controlled signaling events, such as MEK-ERK (data not shown) or AKT phosphorylation ([Figs. 5](#f0025){ref-type="fig"}e, S4 and S5), we posit that RIOK1 does not directly interact with RAS proximal effectors such as Raf or PI3K. Instead we suggest that RIOK1 rather engages in a functional relationship with constitutively active RAS in nematodes and mammalian cells.

In the present study, we also provide insights into the hardly characterized RIOK1 interactome in cancer cells ([Fig. 5](#f0025){ref-type="fig"}c and [Table S1](#ec0010){ref-type="supplementary-material"}). Using co-immunoprecipitation, we confirmed the well-described interaction of PRMT5 with RIOK1 ([@bb0125]), thereby validating our approach (Fig. S12). Furthermore, we observed a protein-protein interaction of wildtype and catalytically inactive RIOK1 not only with the well-established PRMT5 interaction partner but also with itself and RIOK3, suggesting the formation of homo- and hetero-dimers as already reported by Kiburu and LaRonde-LeBlanc ([@bb0170]). Given the fact that many kinases are activated by dimerization ([@bb0030], [@bb0335]), one can speculate that homo- and/or hetero-dimerization of RIO kinases represents a key step in regulating their activity or expression levels.

By studying the effects of RIOK1 depletion on the (phospho-)proteome, we also provide evidence that the three RIO proteins, despite having non-redundant functions, cross-regulate each other. Interestingly, depletion of RIOK1 was associated with a decrease in RIOK3 levels and an increased expression and an electrophoretic mobility shift of RIOK2. A possible explanation for these observations might be the sequential binding of RIO kinases to the pre-40S ribosomal subunit. As RIOK2 first dissociates from the pre-40S subunit before or after binding of RIOK1, loss of RIOK1 could block the dissociation of RIOK2 accompanied with accumulation of pre-40S particles ([@bb0410]). RIOK3 is reported to bind late to the pre-40S particle most likely after binding of RIOK1 ([@bb0025]). Therefore, loss of RIOK1 would prevent RIOK3 binding to the pre-40S subunit and could lead to degradation of RIOK3. Our data invite for further studies addressing the stoichiometry and post-translational modification patterns of all three RIO kinases.

A striking finding of our study is that RIOK1 is required for the invasive properties of NCI-H1299 and MDA-MB-231 cells in 3D culture and *in vivo*. There are two potential, not mutually exclusive mechanisms explaining the requirement for RIOK1 for this phenotype. Firstly, given recent findings that local mRNA translation represents a key regulatory event in the formation of protrusions of MDA-MB-231 cells ([@bb0260]) and that RIOK1/2 are involved in the export and assembly of 40S ribosomal subunits into the cytoplasm ([@bb0180]), it is conceivable that effector proteins critical for invasion are insufficiently produced in the cellular periphery. Secondly, the loss of invasive growth could be explained by our finding that RIOK1 depletion downregulates tonic NF-κB activity and several proteins linked to NF-κB activation and effector functions ([Fig. 6](#f0030){ref-type="fig"} and Tables S1 and S2). The NF-κB pathway is activated upon several stimuli like inflammation and oncogenic signals, including those trigged by mutant RAS ([@bb0110], [@bb0160]). In this study, we showed that RIOK1 acts in parallel to IKK complexes as its depletion inhibits NF-κB signaling by preventing IκBα phosphorylation and degradation and, as a consequence, translocation of RelA (P65) to the nucleus. Moreover, pharmacological NF-κB pathway inhibition at the level of IKK activation resulted in a very similar 2D and 3D growth phenotype as observed for RIOK1 knockdown. Further evidence for this hypothesis is provided by the reduced expression of the IKK substrate MTDH upon RIOK1 depletion. Although MTDH has been linked to metastases in a variety of tumor entities ([@bb0355]), the exact underlying molecular mechanisms remain elusive. However, several reports implicate MTDH as an activator and also as an NF-κB target gene ([@bb0080], [@bb0185]). Consequently it is conceivable that RIOK1 and MTDH depletion will quench tonic NF-κB signaling triggered by oncogenic RAS. This hypothesis is further strengthened by our preliminary data showing the reduction of several NF-κB regulated cytokines in our cell line models (data not shown) of which several have been also linked to cellular migration. Future studies will decipher the exact role of RIOK1 in NF-κB signaling and of downstream effectors by which RIOK1 promotes the formation of cellular protrusions and metastases. However, we do not rule out that the profound effects of RIOK1 depletion on invasiveness *in vitro* and *in vivo* are of pleiotropic nature.

Regardless of the precise molecular mechanisms underlying the protrusion and metastasis impairing effect of RIOK1 depletion, our data already identify RIOK1 as a potential target for tumor therapy, as [@bb0265] have also recently suggested for *MTAP* deficient tumors. Indeed, RIO kinases exhibit ATPase activity and are, as such, potentially druggable by small-molecule compounds. This makes them better suited than other synthetic lethal targets in RAS signaling networks such as transcription factors ([@bb0040], [@bb0070]). Indeed, specific inhibitors are being developed and have already been shown to effectively compete with ATP and to block auto-phosphorylation activity *in vitro* ([@bb0170], [@bb0290]). However, they still need to be tested especially in the context of cancer cell growth *in vitro* and *in vivo*. Nevertheless, RIOK1 knockdown does neither impair the proliferation of K562 and Caco-2 cells nor the acinar morphogenesis of MCF-10A cells, a delicate process involving various fundamental biological processes ([@bb0060]). This suggests that RIOK1 depletion will not be generally toxic and therefore potentially suitable for therapeutic strategies targeting RIOK1. Indeed, [@bb0265] observed that the growth inhibitory effect of RIOK1 depletion could be rescued in both MTAP pro- and deficient HCT116 lines by complementation with wildtype but not with catalytically inactive RIOK1. This finding identifies the enzymatic activity of this atypical kinase as a potential point for therapeutic intervention. According to our data, such an approach would create vulnerability for RAS-transformed cells, while having little or limited effects on healthy cells. Together with our observation that RIOK1 promotes lung colonization in mice and the differential RIOK1 expression in human tumor tissue specimens, our data invite for further studies addressing RIOK1 in cancer, its prognostic significance and suitability as a drug target.
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